Table 3.

Multivariate analysis of outcomes

Outcome	N (Events/Evaluable)	Hazard Ratio (95% CI)	p-value
Relapse/Progression
Cytogenetics
No abnormality/Standard risk	28/174	1.00	0.01
High risk	32/115	2.15 (1.29–3.58)	0.003
Not tested/unknown	19/67	1.47 (0.82–2.65)	0.19
ISS/DSS
I-II	32/163	1.00	0.55
III	47/189	1.29 (0.82–2.65)	0.19
Disease status pre-AHCT
sCR/CR	15/53	1.00	0.57
VGPR	30/150	0.75 (0.40–1.4)	0.36
PR	27/127	0.66 (0.35–1.25)	0.20
SD/PD	8/25	1.17 (0.49–2.76)	0.73
Mel dose
200	17/104	1.00
140	65/252	1.43 (0.83–2.45)	0.20
Progression-free survival
Cytogenetics
No abnormality/Standard risk	41/174	1.00	0.09
High risk	36/115	1.63 (1.04–2.57)	0.03
Not tested/unknown	20/67	1.08 (0.63–1.85)	0.78
ISS/DSS
I-II	38/163	1.00	0.34
III	59/189	1.36 (0.90–2.05)	0.14
Disease status pre-AHCT
sCR/CR	16/53	1.00	0.88
VGPR	36/150	0.84 (0.46–1.52)	0.56
PR	36/127	0.85 (0.47–1.54)	0.60
SD/PD	9/25	1.20 (0.53–2.72)	0.66
Mel dose
200	21/104	1.00
140	76/252	1.42(0.87–2.31)	0.16
Overall survival
Cytogenetics
No abnormality/Standard risk	20/177	1.00	0.48
High risk	17/116	1.49(0.78–2.85)	0.23
Not tested/unknown	11/67	1.13(0.54–2.37)	0.74
ISS/DSS
I-II	18/166	1.00	0.42
III	30/190	1.49 (0.83–2.68)	0.19
Disease status pre-AHCT
sCR/CR	8/53	1.00	0.93
VGPR	15/151	0.79 (0.33–1.89)	0.60
PR	21/129	1.08 (0.48–2.45)	0.86
SD/PD	4/26	1.03 (0.31–3.43)	0.96
Mel dose
200	10/106	1.00
140	38/254	1.52 (0.75–3.06)	0.25

ISS/DSS- International Staging System/Durie Salmon Stage, sCR- stringent complete response, CR- complete response, VGPR- very good partial response, PR- partial response, SD- stable disease, PD- progression, Mel- high dose melphalan